A Phase 4 interventional study of Epoetin alfa and Standard of Care in Hemostasis, Surgical, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-22.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of the study is to compare the effect of perioperative (the time period describing the duration of a participants surgical procedure) administration of PROCRIT to that of Standard of Care (SOC) on the proportion of participants receiving pRBC (packed red blood cells) transfusions (from the day of surgery to the day of hospital discharge) in participants undergoing elective major abdominal and/or pelvic surgery. Standard of Care is defined as the treatment of participants according to the hospital or institution's policy, but where participants will not receive PROCRIT (Epoetin alfa) or any other erythropoiesis-stimulating agents (ESAs) (agents that stimulate the production of red blood cells in the bone marrow).
This is a randomized (the study medication is assigned by chance), parallel-arm (each group of participants will be treated at the same time), open-label (all people know the identity of the intervention), multicenter study. The study consists of screening phase of 21 days, treatment phase of 15 days, follow-up phase of 28 days. Approximately 110 participants undergoing elective major abdominal and/or pelvic surgery will be enrolled. During the Treatment Phase, eligible participants will be randomly assigned (participants are assigned to a treatment group based on chance) in a 1:1 ratio to either PROCRIT (Epoetin alfa) or the Standard of Care (SOC) group that will not receive any erythropoiesis-stimulating agents (ESAs). Participants will undergo surgery during the Treatment Phase. After surgery, all participants will stay in the study for 4 days (or until hospital discharge) and followed for an additional 28 days (Follow-up Phase). Safety evaluations will include assessment of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination which will be monitored throughout the study. The duration of the study for each participant will be approximately 64 days.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: - Scheduled to undergo elective major abdominal and/or pelvic surgery with anticipated significant perioperative ((the time period describing the duration of a participants surgical procedure) blood loss (eg, greater than 500 cc and at increased risk for blood transfusion) - greater than 10 g/dL and less than or equal to 13 g/dL at screening (Day -13 [13 days prior to surgery] to Day -11) and baseline (Day -10) - Patients with and their partners must practice an effective method of (eg, prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, partner sterilization) before entry and throughout the study - Female patients with reproductive potential must have a negative urine pregnancy test within 7 days of the first dose of PROCRIT - Adequate renal (kidney) and adequate hepatic (liver) function assessed within the 21-day screening period Exclusion Criteria: - No severe Congestive Heart Failure ( Class IV) - No known severe stable or unstable coronary artery disease, or unstable angina - No history of deep venous thrombosis (DVT) or pulmonary embolus (PE) within 12 months before study entry (prior superficial thrombophlebitis is not an exclusion criterion) - No history of cerebrovascular accident (CVA), (TIA), Acute coronary syndrome (unstable Angina, myocardial Infarction), or other arterial thrombosis within 6 months before study entry - Not anticipated to donate perioperative autologous blood or receive transfusions within 21 days prior to baseline or to have greater than 6 transfusions perioperatively - No prior treatment with PROCRIT or any erythropoiesis-stimulating agents (ESAs) within the previous month
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive PROCRIT (epoetin alfa).
Drug: Epoetin alfa
Participants will receive standard of care.
Drug: Standard of Care
Participants will receive epoetin alfa 300 IU/kg once daily subcutaneously for 10 days prior to surgery, on the day of surgery, and for four days after surgery.
Also known as: PROCRIT
Participants will receive standard of care based on the Institution's treatment policy.
Number of Participants Receiving pRBC (Packed Red Blood Cell) Transfusions
Time frame: Day of surgery until hospital discharge
Hemoglobin Change From Baseline to End of Study
End of Study Hemoglobin minus baseline Hemoglobin
Time frame: Baseline (Day-10) to end of study (Day 32)
Number of pRBC Units Transfused During Study
Time frame: Baseline (Day -10) to end of study (Day 32)
Hospital Length of Stay
Time frame: Surgery to hospital discharge
| Milestone | PROCRIT (Epoetin Alfa) | STANDARD THERAPY |
|---|---|---|
| Started | 18 | 19 |
| Completed | 14 | 13 |
| Not completed | 4 | 6 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| participants | PROCRIT (Epoetin Alfa) | STANDARD THERAPY |
|---|---|---|
| Number of Participants Receiving pRBC (Packed Red Blood Cell) Transfusions | 4 | 9 |
End of Study Hemoglobin minus baseline Hemoglobin
| g/dL | PROCRIT (Epoetin Alfa) | STANDARD THERAPY |
|---|---|---|
| Hemoglobin Change From Baseline to End of Study | 0.98 ± 1.39 | 0.33 ± 2.06 |
| units | PROCRIT (Epoetin Alfa) | STANDARD THERAPY |
|---|---|---|
| Number of pRBC Units Transfused During Study | 3.5 ± 3.00 | 6.11 ± 7.98 |
| days | PROCRIT (Epoetin Alfa) | STANDARD THERAPY |
|---|---|---|
| Hospital Length of Stay | 7.94 ± 5.17 | 12.56 ± 12.30 |
Collected over 64 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PROCRIT (Epoetin Alfa) | — | 5/18 (27.8%) | 18/18 (100%) |
| STANDARD THERAPY | — | 8/19 (42.1%) | 13/19 (68.4%) |
| Event | PROCRIT (Epoetin Alfa) | STANDARD THERAPY |
|---|---|---|
| Postoperative ileusInjury, poisoning and procedural complications | 2/18 | 0/19 |
| Failure to thriveMetabolism and nutrition disorders | 0/18 | 2/19 |
| Abdominal abscessInfections and infestations | 1/18 | 0/19 |
| Wound dehiscenceInjury, poisoning and procedural complications | 1/18 | 0/19 |
| Renal failureRenal and urinary disorders | 1/18 | 0/19 |
| Ureteric obstructionRenal and urinary disorders | 1/18 | 0/19 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/18 | 0/19 |
| Device dislocationInjury, poisoning and procedural complications | 0/18 | 1/19 |
| Anticoagulation drug level below therapurticInvestigations | 0/18 | 1/19 |
| International normalized ratio increasedInvestigations | 0/18 | 1/19 |
| Event | PROCRIT (Epoetin Alfa) | STANDARD THERAPY |
|---|---|---|
| PyrexiaGeneral disorders | 2/18 | 7/19 |
| NauseaGastrointestinal disorders | 6/18 | 6/19 |
| Procedural hypotensionInjury, poisoning and procedural complications | 3/18 | 5/19 |
| Procedural painInjury, poisoning and procedural complications | 2/18 | 5/19 |
| VomitingGastrointestinal disorders | 4/18 | 2/19 |
| HypotensionVascular disorders | 4/18 | 1/19 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/18 | 2/19 |
| Procedural hypertensionInjury, poisoning and procedural complications | 1/18 | 3/19 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/18 | 3/19 |
| TachycardiaCardiac disorders | 2/18 | 2/19 |
| Age, Categorical(Participants) | PROCRIT (Epoetin Alfa) | STANDARD THERAPY | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 12 | 23 |
| >=65 years | 7 | 7 | 14 |
| Age Continuous(years) | PROCRIT (Epoetin Alfa) | STANDARD THERAPY | Total |
|---|---|---|---|
| Mean | 63.06 ± 16.17 | 61.42 ± 18.32 | 62.22 ± 17.08 |
| Sex: Female, Male(Participants) | PROCRIT (Epoetin Alfa) | STANDARD THERAPY | Total |
|---|---|---|---|
| Female | 13 | 10 | 23 |
| Male | 5 | 9 | 14 |
| Race/Ethnicity, Customized(participants) | PROCRIT (Epoetin Alfa) | STANDARD THERAPY | Total |
|---|---|---|---|
| Black or Aftrican American | 0 | 5 | 5 |
| Other | 1 | 2 | 3 |
| White | 17 | 12 | 29 |
No study locations are listed for this record.
The record gives a start of Aug 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →